These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34430621)

  • 1. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy.
    Xing X; Zhou X; Yang Y; Li Y; Hu C; Shen C
    Ann Transl Med; 2021 Jul; 9(14):1180. PubMed ID: 34430621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
    Liu T; Sun Q; Chen J; Wang F; Li B; Qin W; Ye Z; Hu F
    Cancer Manag Res; 2018; 10():6237-6245. PubMed ID: 30538570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
    Fangzheng W; Chuner J; Lei W; Fengqin Y; Zhimin Y; Quanquan S; Tongxin L; Min X; Peng W; Bin L; Aizawa R; Sakamoto M; Zhenfu F
    Oncotarget; 2017 Oct; 8(53):91150-91161. PubMed ID: 29207632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Du C; Ying H; Zhou J; Hu C; Zhang Y
    Int J Clin Oncol; 2013 Jun; 18(3):464-71. PubMed ID: 22527846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
    Hung CJ; Kang BH; Chang KM; Kang YY; Yin CH; Lee CC
    BMC Cancer; 2022 Oct; 22(1):1084. PubMed ID: 36271346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer.
    Halvorsen TO; Valan CD; Slaaen M; Grønberg BH
    J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1283-1290. PubMed ID: 32725772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis.
    Zhang J; Peng H; Chen L; Li WF; Mao YP; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    J Cancer; 2017; 8(13):2587-2594. PubMed ID: 28900496
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma.
    Guo L; Lin HX; Xu M; Chen QY; Wang CT; Huang PY
    Chin J Cancer; 2010 Feb; 29(2):136-9. PubMed ID: 20109339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Yuan TZ; Zheng RH
    J Cancer; 2021; 12(1):18-27. PubMed ID: 33391399
    [No Abstract]   [Full Text] [Related]  

  • 12. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.
    Huang X; Lv LN; Zhao Y; Li L; Zhu XD
    Clin Nutr; 2021 Jan; 40(1):295-302. PubMed ID: 32507513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
    Liao JF; Zhang Q; Du XJ; Lan M; Liu S; Xia YF; Cai XY; Luo W
    Cancer Commun (Lond); 2019 Jun; 39(1):40. PubMed ID: 31248459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Rimar KJ; Glaser AP; Kundu S; Schaeffer EM; Meeks J; Psutka SP
    Bladder Cancer; 2018 Oct; 4(4):411-418. PubMed ID: 30417052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yang J; Han J; He J; Duan B; Gou Q; Ai P; Liu L; Li Y; Ren K; Wang F; Yao M; Chen N
    Front Oncol; 2020; 10():594756. PubMed ID: 33425747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
    Yao JJ; Yu XL; Zhang F; Zhang WJ; Zhou GQ; Tang LL; Mao YP; Chen L; Ma J; Sun Y
    Chin J Cancer; 2017 Mar; 36(1):26. PubMed ID: 28264724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.
    Jin T; Zhang Q; Jiang F; Qin WF; Jin QF; Cao CN; Piao YF; Feng XL; Luo W; Chen XZ
    Oncotarget; 2017 Nov; 8(59):100764-100772. PubMed ID: 29246020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
    Fangzheng W; Chuner J; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Sakamoto M; Peng W; Kaiyuan S; Weifeng Q; Zhenfu F; Yangming J
    Oncotarget; 2017 Dec; 8(70):115469-115479. PubMed ID: 29383174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.